Equity Research
William Blair research analyst Andy Hsieh was quoted by Bloomberg following the recent earnings report from biopharma company Viking Therapeutics.
“While Viking’s drug must still undergo late-stage testing, the results exceeded expectations, indicating it may end up being more effective than Zepbound,” Hsieh’s note to investors that was quoted by the publication said.
Stay up-to-date with the latest William Blair news and insights
Jed Dorsheimer welcomes Doomberg for an in-depth discussion on the complexities of renewable energy integration and its impact on grid efficiency, exploring the challenges posed by the variability of renewables, the resurgence of nuclear power, and the critical role of natural gas in bridging the energy transition.
William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, is thrilled to announce its performance in the annual Coalition Greenwich Voice of the Client – 2024 North American Equity Investors Study.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
